Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: J Pharm Sci. 2021 Jun 2;110(10):3331–3344. doi: 10.1016/j.xphs.2021.05.018

Figure 2.

Figure 2.

Recommendation for evaluation of protein binding in the clinical development. The role of PPB on efficacy models needs to be rigorously evaluated and established throughout the preclinical and clinical development stages as suggested and outlined by this general scheme. PPB: plasma protein binding; NTI: narrow therapeutic index.3 Reproduced with permission from [3].